07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

AdeTherapeutics dermatology news

Wound healing company AdeTherapeutics engaged investment bank Beal Advisors to explore strategic alternatives including partnerships for all or part of its pipeline, a series A financing, merger or sale. AdeTherapeutics said it has been approached...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

AdeTherapeutics, Royal DSM deal

Royal DSM will use its polyesteramide biomaterial technology to develop AdeTherapeutics preclinical products for scar reduction and pain management. The partnership will focus on developing therapeutics to reduce scar tissue formation after spinal surgery. Details...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

Evitar: Phase I start

This month, AdeTherapeutics will begin a double-blind, placebo-controlled, Canadian Phase I trial to evaluate 1 g/kg intraperitoneal Evitar in 38 patients. AdeTherapeutics Inc., Saskatoon, Saskatchewan   Product: Evitar   Business: Dermatology   Molecular target: NA   Description: Modulates...